Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 16, 2025

Using systems biology and drug repositioning approaches to discover FDA-approved drugs candidates for endometriosis treatment.

View Full Paper
Ask AI
Bookmark
Share

Authors

SSSamira SanamiSemnan University of Medical SciencesSAShahrzad AghaamooSemnan University of Medical SciencesSASajjad AhmadSouth China Agricultural University

Discussion

Loading...

Member takes

Implication

Systems biology reveals potential therapies targeting VEGFR2 in endometriosis, suggesting further investigation is needed.

Key Points

  • Ponatinib shows promise in targeting VEGFR2 for endometriosis treatment, highlighting its potential effectiveness.
  • Molecular docking revealed ponatinib's binding energy of -9.6 kcal/mol, favorable compared to the co-crystal ligand.
  • Functional analysis identified 708 up-regulated and 414 down-regulated differentially expressed genes related to endometriosis.
  • Further experimental investigations are necessary to confirm the therapeutic efficacy of ponatinib for endometriosis.

Cite This Study

Sanami et al. (2025) studied this question.

synapsesocial.com/papers/68c93fee01120bef803bb1a9https://doi.org/10.1371/journal.pone.0330841
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1DAVID: a web server for functional enrichment analysis and functional annotation of gene lists (2021 update)2022 · 6,663 citations
  2. 2ProLIF: a library to encode molecular interactions as fingerprints2021 · 459 citations
  3. 3UCSF Chimera—A visualization system for exploratory research and analysis2004 · 48,907 citations
  4. 4Stress detection using deep neural networks2020 · 193 citations
  5. 5IL-6/IL-6 receptor system and its role in physiological and pathological conditions2011 · 932 citations